Intercept Pharmaceuticals
Intercept Pharmaceuticals's Overview
Intercept Pharmaceuticals, acquired by Alfasigma S.p.A. in November 2023, is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for progressive non-viral liver diseases. Their flagship product, Ocaliva (obeticholic acid), is approved for primary biliary cholangitis (PBC). The company has a strong research focus on addressing unmet medical needs in complex liver conditions, now continuing its mission as an integral part of Alfasigma's global operations.
Where is Intercept Pharmaceuticals's Headquarters?
HQ Function
Serves as a significant operational center for Alfasigma's liver disease franchise in the United States, housing administrative, commercial, and R&D support functions related to former Intercept activities.
Notable Features:
Modern office space in a multi-tenant building, equipped to support biopharmaceutical operations. Specific architectural highlights are not publicly prominent as it's typically leased and fitted-out commercial space.
Work Culture:
A culture historically rooted in scientific innovation and patient-centricity, focused on tackling challenging liver diseases. Post-acquisition, this is integrating with Alfasigma's broader corporate culture and values.
HQ Significance:
Represents a key hub for Alfasigma's presence in the U.S. liver disease market, leveraging Intercept's established expertise, product portfolio, and research capabilities.
Values Reflected in HQ: Commitment to scientific advancement in hepatology, focus on addressing unmet patient needs in liver diseases, and operational integration within a larger global pharmaceutical organization.
Location:
As part of Alfasigma S.p.A., Intercept Pharmaceuticals contributes to a significant global presence, particularly in North America and Europe. Functions supported globally include research and development in liver diseases, clinical trial management, medical affairs, regulatory submissions, and commercial operations for its specialized therapeutics.
Street Address:
305 Madison Avenue
City:
Morristown
State/Province:
NJ
Country:
USA
Intercept Pharmaceuticals's Global Presence
London, UK
Address: Intercept Pharma Europe Ltd., The Economist Building, 25 St James's Street, London, SW1A 1HG, UK
To lead and coordinate Alfasigma's liver disease therapeutic area activities in Europe and other ex-US international markets, ensuring market access and delivery of therapies to patients.
Buying Intent Signals for Intercept Pharmaceuticals
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
Executive Team of Intercept Pharmaceuticals
As of April 2025, Intercept Pharmaceuticals' leadership includes:
Investors of Intercept Pharmaceuticals
Intercept Pharmaceuticals has been backed by several prominent investors over the years, including:
Executive New Hires/Exits in the Last 12 Months
Following its acquisition by Alfasigma S.p.A. in November 2023, Intercept Pharmaceuticals' standalone executive team was dissolved. Former CEO Jerome Durso departed, and oversight transitioned to Alfasigma's leadership, including Pier Vincenzo Colli (CEO, Alfasigma S.p.A.) and Bryan J. Smith (President & GM, Alfasigma USA).
Departures
New Appointments:
Technology (Tech Stack) used by Intercept Pharmaceuticals
Discover the tools Intercept Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Intercept Pharmaceuticals Email Formats and Examples
While Intercept Pharmaceuticals is now part of Alfasigma, historical email formats at Intercept often followed common corporate structures. A widely used pattern is combining the first initial with the last name. For current Alfasigma communications, their specific email format would apply.
[first_initial][last]@interceptpharma.com
Format
jdoe@interceptpharma.com
Example
70%
Success rate
News and media
Alfasigma Press Release • June 5, 2024
Alfasigma Presents New Ocaliva® (obeticholic acid) Data at EASL Congress 2024
Alfasigma announced new data presentations for Ocaliva® (obeticholic acid) at The International Liver Congress™ (ILC), EASL Congress 2024, highlighting its ongoing commitment to primary biliary cholangitis (PBC) research and treatment. The data reinforce the long-term efficacy and safety profile of Ocaliva....more
Fierce Pharma • November 8, 2023
Alfasigma Completes $1.9B Acquisition of Intercept Pharmaceuticals
Alfasigma S.p.A. finalized its acquisition of Intercept Pharmaceuticals for $1.9 billion ($19.00 per share in cash). This strategic move significantly expands Alfasigma's gastroenterology and hepatology portfolio, notably adding Ocaliva, a treatment for primary biliary cholangitis....more
Endpoints News • June 23, 2023
FDA Again Rejects Intercept Pharmaceuticals' NASH Drug Candidate Obeticholic Acid
Intercept Pharmaceuticals received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for obeticholic acid (OCA) for pre-cirrhotic fibrosis due to nonalcoholic steatohepatitis (NASH). This marked the second FDA rejection for OCA in this indication....more
Highperformr’s free tools for company research
Explore Employees by Region or Country
See where a company’s workforce is located, by country or region.
View Funding Details
View past and recent funding rounds with amounts and investors.
Understand Revenue Insights
Understand company revenue estimates and financial scale.
Track Active Job Openings
Track active roles and hiring trends to spot growth signals.
Review Product and Offerings
Discover what a company offers—products, platforms, and solutions.
Get SIC or NAICS Codes
Get the company’s official SIC and NAICS classifications.
Analyze Website Traffic Trends
Analyze visitor volume, engagement, and top traffic sources.
Discover Social Profiles and Engagement
Explore LinkedIn, Twitter, and other active social profiles.
Identify Top Competitors
Identify top competitors based on similar business traits.
Research and Discover Companies with Highperformr — Smarter, Faster
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
- Track intent signals to find buyers who are actively in-market
- Enrich contacts and companies instantly, no need to switch tools
- Automate workflows to stay ahead of every change
- Connect your CRM & tools for seamless data sync and activation
Thousands of companies, including Intercept Pharmaceuticals, are just a search away.